DISPATCHES FROM BIO 2016

US FDA Commissioner Califf calls on industry to tackle supply chain quality issues

By Dan Stanton contact

- Last updated on GMT

Califf don't like it: poor supply chain management. FDA Commish wants more industry effort
Califf don't like it: poor supply chain management. FDA Commish wants more industry effort

Related tags: Inspection, Food and drug administration

Risk algorithms and international agreements will help ensure imported API quality, says FDA Commissioner Robert Califf but industry must also take responsibility for its own supply chain.

At a packed fireside chat at BIO this week, US Food and Drug Administration (FDA) Commissioner Robert Califf was reminded of the heparin scandal in 2008 where adulterated API imported from China was linked to 81 deaths in the US.

While this has led to greater FDA scrutiny​ across the pharma supply chain, including increased funding​ for overseas inspection units, Califf was challenged as to how the Agency will continue to try to ensure the safety of foreign-made APIs.

“We are revamping the inspections system, there will be many more inspections in India and China,” ​he told the San Franciscan crowd, adding the Agency is using a “risk algorithm”​ technology to help the inspectorate team in its approach to visiting facilities.

“We’re getting more and more data into the system​,” he said, but did not elaborate further. “You’ll hear a lot more about that over the next six months as that comes into place.”

But he acknowledged that quality issues are not restricted to Chinese and Indian API and drugmakers.

“There are problems all over the world not just in those countries so we have to be cognisant of general risk which is the way we have to decide where to inspect,”​ he continued.

“We’re also working on mutual agreements with Europe so that we spend less inspection time in Europe.”

Califf also called on industry itself to take responsibility for the quality of its supply chains.

“These firms that are making APIs are part of a supply chain which is essentially owned by the companies that eventually sell and distribute the drugs, so there’s a lot to be done by the companies themselves to make sure their suppliers are up to standard.

“We need to develop a better ecosystem of quality to deal with these issues.”

Related news

Show more

Related products

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more